���构特征与受体作用机制 — Common Mistakes

By Editorial Desk · published 2026-04-22 · last reviewed 2026-05-07 · Info

This is a working overview of peptide analogue, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-05-07 and is reviewed periodically as new material appears.

结构特征与受体作用机制

皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。

Background and Drug Class

Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.

Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.

Semaglutide at a glance

Mechanism and Pharmacological Class

Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.

Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.

Related pages on this site

• Efficient collection
• Efficient collection
• Verified digest
• Measured playbook
• Modern workbook
• Focused workbook
• Professional archive
• Portable workbook

Background and Mechanism of Action

Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.

Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.

Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.

Semaglutide Structure and Receptor Mechanism

Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.

Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.

Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.

Background and Molecular Design

Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.

The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.

Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.

Further detail

=== Tag === The tag may be either a direct reporter, such as a fluorophore, or an affinity label such as biotin, or it may consist of a latent handle like an alkyne or azide for use with Huisgen 1,3-dipolar cycloaddition (also known as click chemistry). Reporter tags facilitate detection and isolation of labeled proteins. Common examples include fluorophores used for visualization via in-gel fluorescence and high-throughput gel-based screens, biotin for streptavidin-based enrichment followed by mass spectrometry, and isotopic labels for quantitative mass spectrometry. Alternatively, alkynes or azides can be incorporated as bio-orthogonal handles for post-labeling conjugation via click chemistry, enabling modular addition of fluorophores, affinity tags, or isotopic labels after proteome labeling. These "clickable" designs minimize steric hindrance at the active site and expand analytical flexibility, particularly for high-resolution liquid chromatography-mass spectrometry methods.

This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once. Brand names and generic names are differentiated by capitalizing brand names. See also the list of the top 100 bestselling branded drugs, ranked by sales. Abbreviations are used in the list as follows:

== Education == Pediatric dentistry is one of the ten dental specialties recognized by American Dental Association. Other specialties include dental public health, endodontics, oral and maxillofacial pathology, oral and maxillofacial radiology, oral and maxillofacial surgery, orthodontics and dentofacial orthopedics, periodontics, and prosthodontics. The first step would be obtaining a college degree in biomedical science, health science, or social science as long as all biomedical course pre-requisites are met courses. While in college, one can explore the profession by shadowing in a pediatric dental office or children's hospital, or working on academic research that studies oral health of children. Second step would be attending a dental school that involves four years of education and training. One can graduate with Doctor of Dental Surgery (DDS) or Doctor of Dental Medicine (DMD). Both degrees are equivalent and people receive the same training as required by the CODA (Commission on Dental Accreditation). During the first two years of dental school, dental students will take didactic classes on biomedical sciences and hands on classes to learn technical procedures in a pre-clinical laboratory setting. Third and fourth years of dental school focus on clinical care under the supervision of attending faculty who are licensed dentists. Before graduating, all dental students must pass National Board Dental Examination part I and part II, as well as clinical skill exams (e.g., ADEX, WREB, etc) to become a licensed general dentist.

Kobai Yukiyanagi (雪柳 紅梅, Yukiyanagi Kōbai) Voiced by: Kana Hanazawa (Japanese); Monica Rial (English) Former Agent of Spring and Hinagiku's mother. She fell in love with Shungetsu, with whom she had Hinagiku, but this gave rise to a series of disagreements within the village. She later committed suicide to end the discrimination and mistreatment toward her and her daughter. Shungetsu Kayo (花葉 春月, Kayō Shungetsu) Voiced by: Kōji Yusa Head of the Kayo family. He's the father of Hinagiku and Zansetsu. He is as cold as Winter, probably the reason Kobai fell in love with him. His beloved's death has sparked an aversion to Hinagiku, who he ignores even though he officially acknowledged her. Zansetsu Kayo (花葉 残雪, Kayō Zansetsu) Spring Village Administrator. He's Hinagiku's half-brother. He's a wealthy boy, and his mother's a prosperous landowner. He knows Sakura and asks her to keep her sister unaware of the financial support he is providing to the two girls. Tsubame Aboshi (阿星 燕, Aboshi Tsubame) Zansetsu's servant. He grew up in the same orphanage as Sakura before being taken in by Zansetsu, whom he worships almost religiously. Despite his age, he performs his duties better than most adults in the village.

3,4,5-Trimethoxyamphetamine (TMA, TMA-1, or 3,4,5-TMA), also known as α-methylmescaline (3C-mescaline or 3C-M) or mescalamphetamine, is a psychedelic drug of the phenethylamine and amphetamine families. It is one of the trimethoxyamphetamine (TMA) series of positional isomers. The drug is notable in being the amphetamine (α-methylated) analogue of mescaline (3,4,5-trimethoxyphenethylamine).

Sources: en.wikipedia.org

Background from the literature

Five recognized "nuclear-weapon states" under the terms of the Nuclear Non-Proliferation Treaty (NPT): the United States (first nuclear weapon tested and two bombs used as weapons in 1945), Russia (first weapon tested in 1949), the United Kingdom (1952), France (1960), and China (1964) Three other declared nuclear states that are not signatories of the NPT: India (not a signatory, weapon tested in 1974), Pakistan (not a signatory, weapon tested in 1998), and North Korea (withdrew from the NPT in 2003, weapon tested in 2006) Israel, which is widely known to have developed nuclear weapons (likely first tested in the 1960s or 1970s) but has not openly declared its capability South Africa, which also had enrichment capabilities and developed nuclear weapons (possibly tested in 1979), but disassembled its arsenal and joined the NPT in 1991

== Electrochemistry == The electrochemical reactants in a lithium-ion cell are the materials of the electrodes, both of which are compounds containing lithium atoms. Although many thousands of different materials have been investigated, only a very small number are commercially usable. All commercial Li-ion cells use intercalation compounds as active materials. The negative electrode is usually graphite, although silicon is often mixed in to increase the capacity. The electrolyte is usually lithium hexafluorophosphate, dissolved in a mixture of organic carbonates. A number of different materials are used for the positive electrode, such as LiCoO2, LiFePO4, and lithium nickel manganese cobalt oxides. During cell discharge the negative electrode is the anode and the positive electrode the cathode: electrons flow from the anode to the cathode through the external circuit. An oxidation half-reaction at the anode produces positively charged lithium ions and negatively charged electrons. The oxidation half-reaction may also produce uncharged material that remains at the anode. Lithium ions move through the electrolyte; electrons move through the external circuit toward the cathode where they recombine with the cathode material in a reduction half-reaction. The electrolyte provides a conductive medium for lithium ions but does not partake in the electrochemical reaction. The reactions during discharge lower the chemical potential of the cell, so discharging transfers energy from the cell to wherever the electric current dissipates its energy, mostly in the external circuit.

Optical storage uses lasers to store and retrieve data. Recordable CDs, DVDs, and Blu-ray Discs are commonly used with personal computers and are generally cheap. The capacities and speeds of these discs have typically been lower than hard disks or tapes. Advances in optical media may shrink that gap in the future. Potential future data losses caused by gradual media degradation can be predicted by measuring the rate of correctable minor data errors, of which consecutively too many increase the risk of uncorrectable sectors. Support for error scanning varies among optical drive vendors. Many optical disc formats are WORM type, which makes them useful for archival purposes since the data cannot be changed in any way, including by user error and by malware such as ransomware. Moreover, optical discs are not vulnerable to head crashes, magnetism, imminent water ingress or power surges; and, a fault of the drive typically just halts the spinning. Optical media is modular; the storage controller is not tied to media itself like with hard drives or flash storage (→flash memory controller), allowing it to be removed and accessed through a different drive. However, recordable media may degrade earlier under long-term exposure to light. Some optical storage systems allow for cataloged data backups without human contact with the discs, allowing for longer data integrity. A French study in 2008 indicated that the lifespan of typically-sold CD-Rs was 2–10 years, but one manufacturer later estimated the longevity of its CD-Rs with a gold-sputtered layer to be as high as 100 years.

== Production == Four chemical processes contribute to industrial benzene production: catalytic reforming, toluene hydrodealkylation, toluene disproportionation, and steam cracking etc. According to the ATSDR Toxicological Profile for benzene, between 1978 and 1981, catalytic reformates accounted for approximately 44–50% of the total US benzene production.

Tertiary structure may give way to the formation of quaternary structure in some proteins, which usually involves the "assembly" or "coassembly" of subunits that have already folded; in other words, multiple polypeptide chains could interact to form a fully functional quaternary protein.

Sources: en.wikipedia.org

Frequently asked questions